0.7502

0.64% -0.0048

Xilio Therapeutics Inc (XLO)

Overview News Price History Financials Discussions Forecast

Xilio Therapeutics Inc stock is traded at $0.7502, with a volume of 56,158. It is down -0.64% in the last 24 hours and up +2.60% over the past month. Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Previous Close:

$0.755

Open:

$0.7466

24h Volume:

56,158

Relative Volume:

0.02

Market Cap:

$42.89M

Revenue:

Net Income/Loss:

$-81.22M

P/E Ratio:

-0.2534

EPS:

-2.96

Net Cash Flow:

$-74.41M

1W Performance:

-9.45%

1M Performance:

+2.60%

6M Performance:

-43.17%

1Y Performance:

-28.55%

1-Day Range:

$0.7466

$0.7784

1-Week Range:

$0.7143

$0.84

52-Week Range:

$0.62

$1.70

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name

Xilio Therapeutics Inc

Sector

Healthcare (1152)

Industry

Biotechnology (677)

Phone

617-833-1027

Address

828 WINTER STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2024-11-09

Latest SEC Filings

XLO's Discussions on Twitter

Compare XLO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XLO Xilio Therapeutics Inc	0.7502	42.89M	0	-81.22M	-74.41M	-2.96
VRTX Vertex Pharmaceuticals Inc	501.15	126.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	605.61	65.06B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	649.67	37.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	259.39	32.56B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	255.77	26.40B	3.81B	-644.79M	-669.77M	-6.24

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-21-22	Initiated	Chardan Capital Markets	Buy
Jan-10-22	Initiated	H.C. Wainwright	Buy
Nov-16-21	Initiated	Cowen	Outperform
Nov-16-21	Initiated	Guggenheim	Buy
Nov-16-21	Initiated	Morgan Stanley	Overweight
Nov-16-21	Initiated	Raymond James	Outperform

View All

Xilio Therapeutics Inc Stock (XLO) Latest News

May 03, 2025

Geode Capital Management LLC Acquires 20,230 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World

May 03, 2025

May 02, 2025

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail

May 02, 2025

Xilio Therapeutics Awards 5,000 Share Stock Option Grant at $0.755 Per Share to New Employee - Stock Titan

May 02, 2025

May 01, 2025

Xilio’s Stacey Davis recruited by Enara - The Pharma Letter

May 01, 2025

Apr 23, 2025

Xilio Therapeutics to Present Updated Phase 2 Data for - GlobeNewswire

Apr 23, 2025

Xilio Therapeutics Announces Presentation of Phase 2 Data for Vilastobart and Atezolizumab at 2025 ASCO Annual Meeting - Nasdaq

Apr 23, 2025

Phase 2 Trial Results: Novel Tumor-Activated Therapy Shows Promise in Hard-to-Treat Colorectal Cancer - Stock Titan

Apr 23, 2025

Apr 14, 2025

50,086 Shares in Xilio Therapeutics, Inc. (NASDAQ:XLO) Bought by Raymond James Financial Inc. - Defense World

Apr 14, 2025

Apr 09, 2025

Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com India

Apr 09, 2025

Apr 08, 2025

Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada

Apr 08, 2025

Apr 05, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 05, 2025

Apr 04, 2025

Xilio Expands Immuno-Oncology Team: 23K Shares Granted to New Biotech Talent - Stock Titan

Apr 04, 2025

Apr 02, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 17.1% in March - Defense World

Apr 02, 2025

Mar 31, 2025

Xilio Therapeutics (XLO) to Release Quarterly Earnings on Monday - Defense World

Mar 31, 2025

Mar 25, 2025

Head to Head Contrast: Xilio Therapeutics (NASDAQ:XLO) and Janone (NASDAQ:ALTS) - Defense World

Mar 25, 2025

Mar 20, 2025

Deals In Depth: February 2025 - insights.citeline.com

Mar 20, 2025

Mar 18, 2025

Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks

Mar 18, 2025

Mar 13, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World

Mar 13, 2025

Mar 12, 2025

Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating for Xilio Therapeutics - TipRanks

Mar 12, 2025

Mar 11, 2025

Xilio advances cancer treatments, secures AbbVie collaboration By Investing.com - Investing.com Australia

Mar 11, 2025

Xilio Therapeutics May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time - Marketscreener.com

Mar 11, 2025

Xilio Therapeutics inks $50M sales agreement with Leerink Partners - Investing.com India

Mar 11, 2025

Xilio Therapeutics inks $50M sales agreement with Leerink Partners By Investing.com - Investing.com UK

Mar 11, 2025

Form 424B5 Xilio Therapeutics, Inc. - StreetInsider.com

Mar 11, 2025